Effect of luteinizing hormone-releasing hormone agonists on the testosterone levels and quality of life in patients with locally advanced and generalized prostate cancer

Full Text

Abstract

Prostate cancer (PC) was 5% of all revealed male malignancies in the Russian Federation in 2009. Among 23845 detected patients with PC, 53.4% had its Stage III or IV.
This paper gives the results of a follow-up of patients with locally advanced and generalized PC treated by different hormonal therapy regimens. The purpose of the study was to search for the optimal hormonal therapy regimen, by maintaining the quality of life, whose criteria were potency level, libido, and normal physical activity.
The follow-up data may lead to the conclusion that the 6-month use of luteinizing hormone-releasing hormone (LHRH) agonists causes an irreversible reduction in potency and libido and a considerable decrease in testosterone levels. Sustained-release LHRH agonists decrease testosterone levels (below 20 ng/dl), are an easy-to-use and simple dosage form, and may be recommended for outpatient administration.

References

  1. Ганов Д. И., Татьянин В. В., Пьянкова Н. Ю. К вопросу качества жизни больных раком предстательной железы. - Барнаул, 2001.
  2. Гарин А. М. Принципы и возможности современной эндокринной терапии опухолей. - М., 2000. - С. 109-129.
  3. Злокачественные новообразованияв России в 2009 г. (заболеваемость и смертность) / Под ред. В. И. Чиссова и др. - М., 2010. - С. 98.
  4. Карякин О. Б. // Материалы 3-й Всероссийской науч. конф. с участием стран СНГ "Актуальные вопросы лечения онкоурологических заболеваний". - М., 1999. - С. 52-54.
  5. Матвеев Б. П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы: Метод. рекомендации. - М., 2000.
  6. Состояние онкологической помощи населению России в 2009 г. / Под ред. В. И. Чиссова и др. - М., 2010. - С. 104.
  7. Akakura K., Bruchovsky N. et al. // J. Steroid. Biochem. Mol. Biol. - 1996. - Vol. 59, N 5-6. - P. 501-511.
  8. Albrecht W., Collette L., Fava C. et al. // Eur. Urol. - 2003. - Vol. 44, N 5. - P. 505-511.
  9. Barabutis N., Schally A. V. et al. // Cell Cycle. - 2010. - Vol. 9, N 20. - P. 4110-4116.
  10. Bouchot O., Lenormand L., Karam G. et al. // Eur. Urol. - 2000. - Vol. 38, N 5. - P. 543-549.
  11. Bruchovsky N., Klotz L. H., Crook J. M. et al. // Renal, Bladder and Prostate Cancer / Eds K. H. Kurth et al. - London, 1998. - P. 173-182.
  12. Cunha G. R., Foster B., Thomson A. et al. // Wld J. Urol. - 1995. - Vol. 13, N 5. - P. 264-276.
  13. Daniell H. W. // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 439-444.
  14. Dawson N. A., McLeod D. G. // Eur. J. Cancer. - 1997. - Vol. 33, N 4. - P. 560-565.
  15. Gleave M., Bruchovsky N., Goldenberg S. L., Rennie P. // Eur. Urol. - 1998. - Vol. 34. - Suppl. 3. - P. 37-41.
  16. Higano C. S., Ellis W., Russell K. et al. // J. Clin. Oncol. - 1993. - Vol. 11. - P. 570-579.
  17. Kaisary A., Tyrrell C., Peeling W., Griffith K. // Br. J. Urol. - 1992. - Vol. 67. - P. 502-508.
  18. Noble R. L. // Cancer Res. - 1977. - Vol. 37, N 1. - P. 82- 94.
  19. Schröder F. H. // Urol. Oncol. - 2010. - Vol. 28, N 6. - P. 663-667.

Statistics

Views

Abstract: 125

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2011 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies